Can I initiate losartan (angiotensin‑II receptor blocker) in a patient with an eGFR of 38 mL/min/1.73 m² and a serum potassium of 5.0 mEq/L?

Can You Start Losartan with GFR 38 and Potassium 5.0?

Yes, you can cautiously initiate losartan in this patient, but you must start at a reduced dose (25 mg daily), implement close monitoring, and address the borderline hyperkalemia before or concurrent with initiation.

Clinical Reasoning

Your patient has CKD stage 3b (GFR 38 mL/min/1.73 m²) with borderline hyperkalemia (K+ 5.0 mEq/L). While this scenario requires caution, ARBs like losartan remain nephroprotective and are explicitly recommended even in advanced CKD.

Guideline-Based Approach

KDOQI guidelines specifically address this situation 1:

• Start at a lower dose when GFR < 45 mL/min/1.73 m² (your patient qualifies)
• ARBs should not be routinely discontinued even when GFR < 30 mL/min/1.73 m² as they remain nephroprotective
• The key is proper monitoring, not avoidance

Multiple guidelines confirm ARBs are first-line therapy in CKD with hypertension 2:

• Patients with GFR < 30 mL/min/1.73 m² and hypertension should receive an ACE inhibitor or ARB as first-line therapy (Grade C)
• The 2021 KDIGO Blood Pressure guideline reinforces continuing these agents even in advanced CKD 3

The Potassium Issue

Your patient's potassium of 5.0 mEq/L is at the threshold but not an absolute contraindication:

From the 2013 ACC/AHA Heart Failure guidelines 4:

• Aldosterone antagonists (which carry higher hyperkalemia risk than ARBs) can be initiated if K+ ≤5.0 mEq/L
• For ARBs specifically, the initial dose should only be given if K+ ≤5.0 mEq/L

FDA labeling for losartan 5:

• Warns about hyperkalemia risk, particularly with other potassium-raising agents
• Does not provide an absolute potassium cutoff for initiation
• Emphasizes monitoring rather than avoidance

Practical Implementation Algorithm

Step 1: Pre-initiation Assessment

• Review medications: Stop potassium supplements, potassium-sparing diuretics, or salt substitutes
• Assess volume status and dietary potassium intake
• Rule out renal artery stenosis if clinically suspected
• Ensure patient is not acutely ill, dehydrated, or scheduled for contrast/surgery

Step 2: Dosing Strategy

• Start losartan 25 mg daily (not the standard 50 mg) given GFR < 45 1
• Take with or without food
• Consider starting in the morning to facilitate same-day monitoring if needed

Step 3: Monitoring Protocol 1, 6, 3

• Check GFR and potassium within 1 week of starting therapy (this is critical)
• Repeat at 2-4 weeks after initiation
• Continue monitoring every 3 months once stable

Step 4: Acceptable Changes vs. Red Flags

Acceptable:

• Serum creatinine rise ≤30% within 4 weeks 6, 3
• Potassium rise to 5.5 mEq/L (manageable with dietary modification) 7

Stop or reduce dose if:

• Serum creatinine rises >30% within 4 weeks 6, 3
• Potassium >5.5-6.0 mEq/L despite dietary measures 4
• Symptomatic hypotension develops
• Acute illness requiring volume depletion (temporarily hold)

Evidence on Safety in This Population

Research data supports initiation even in advanced CKD:

A 2013 randomized trial specifically examined patients with stage 3 CKD (mean eGFR 46-48 mL/min/1.73 m²) initiating ARBs 7:

• 37-40% developed potassium >5.0 mEq/L
• Mean potassium increase was only 0.24-0.3 mmol/L
• No patients required drug discontinuation
• Hyperkalemia was managed with dietary potassium restriction

A Japanese study examined losartan in patients with creatinine >3 mg/dL (roughly GFR <30) 8:

• Losartan was safely administered
• Serum potassium elevations were controlled with dietary therapy
• No difference in safety between patients with creatinine >3 vs. <3 mg/dL

Common Pitfalls to Avoid

1. Don't withhold beneficial therapy due to borderline values - The nephroprotective benefits outweigh risks when properly monitored 9

2. Don't combine with other RAAS inhibitors - Dual ACE/ARB therapy increases hyperkalemia and AKI risk without added benefit 5

3. Don't forget to temporarily hold during acute illness - Suspend during vomiting, diarrhea, contrast procedures, or major surgery 1

4. Don't use standard dosing - Starting at 50 mg in this patient would be inappropriate; 25 mg is the correct initial dose 1

5. Don't skip the 1-week follow-up - This is when acute changes in potassium and creatinine are most likely to manifest 6, 3

Adjunctive Strategies

If hyperkalemia becomes problematic during therapy:

• Dietary potassium restriction (<2-3 g/day)
• Loop diuretics if volume overloaded
• Consider potassium binders (patiromer, sodium zirconium cyclosilicate) to enable continuation 9
• Evaluate for metabolic acidosis and treat if present

The 2024 KDIGO CKD guidelines emphasize continuing RASi even when eGFR falls below 30 mL/min/1.73 m² 6, reinforcing that your patient at GFR 38 is well within the range where benefits exceed risks with appropriate monitoring.